GlassScriptPhysician profile
Nicole K Everett
NPI 1518540905
$1,876.53
in general payments reported to CMS, 2019-2025
16 companies · $794 in 2025
The $794 reported for 2025 was more than what 87% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $196 · 2023: $230 · 2024: $657 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,681.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,680.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $341.07 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Sun Pharmaceutical Industries INC. | $322.95 | 2023-2025 | Cequa |
| Alcon Vision LLC | $229.67 | 2023-2025 | Precision 1, Eysuvis, Rocklatan |
| Glaukos Corporation | $208.55 | 2022-2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Tarsus Pharmaceuticals, INC. | $169.05 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $168.15 | 2023-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Ocular Therapeutix, INC. | $120.90 | 2024 | Dextenza |
| Harrow Eye, LLC | $66.28 | 2025 | Vevye |
| Dompe US, INC. | $65.42 | 2022-2025 | Oxervate |
| Abbvie INC. | $45.95 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $40.04 | 2023 | |
| Rxsight INC | $23.02 | 2023 | Rxsight Contact Lens, Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Cartridge |
| Thea Pharma INC. | $22.66 | 2025 | Iyuzeh |
| Coopervision INC. | $19.33 | 2024 | Misight Contact Lens |
| Biotissue Holdings INC. | $17.20 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $16.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Everett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.